Drug ID: 1d00000024
Drug Name: Aclarubicin
Generic Names: Klasinomycin | Aclacinon | Aclacin | Aclacinomycine | Aclaplastin | Jaclacin
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: Adult: IV- Initial: 175-300 mg/m2, divided over 3-7 consecutive days. Maintenance: 25-100 mg/m2 3-4 weekly.
Recommended In: This medication is an anthracycline agent, prescribed for acute non-lymphocytic leukaemia. It has a selective inhibitory effect on the synthesis of RNA in the cells.
Directions For Use: It comes as a solution for injection to be administered by a healthcare provider into the vein.
Storage: IV Inj: Store at room temperature (20 to 25°C). Protect from sunlight.
IV Inj (reconstituted solution): Store below 40°C. Use within 24 hours if kept at room temperature.
Dosage Forms: Intravenous injection
Side Effects: Severe Effects - Heart damage and bone marrow suppression.
Gastrointestinal - Nausea, vomiting, irritant to tissue, sore mouth, diarrhea, and gastrointestinal tract inflammation.
Blood - Anemia, bone-marrow suppression.
Skin - Hair loss.
Liver- Hepatic dysfunction.
Genitourinary - Blood in urine.
In Case of Overdose: No information available with us.
Avoid If: Caution should be exercised in patients with history of liver or kidney impairment, radiation-induced heart attack, and use of radiotherapy, during pregnancy and breastfeeding.
Monitor complete blood counts, liver function, uric acid level in blood regularly while taking this medication.
Avoid live vaccination during the treatment period.
Avoid excess dosage.
Drug Interaction: Other cardiotoxic drugs e.g. daunorubicin or cyclophosphamide, live vaccines; decreases effects of digoxin, oral anticoagulants, phenytoin and suxamethonium.